Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca’s Farxiga Approval In Heart Failure A First For SGLT2 Inhibitors

Oct 22 2019

• By Leah Samuel

Related Content

Market-Changing Launches Expected In 2020

Jun 05 2019

Keeping Track: US FDA, Industry Roar Into Fourth Quarter With Bevy Of Regulatory Announcements

Oct 06 2019

BI Bets On Expanding Jardiance As Diabetes Drug Sales Soar

Apr 18 2019

AstraZeneca’s Farxiga Fails To Get FDA OK As Insulin Supplement In Type 1 Diabetes

Jul 15 2019

Farxiga Data Change Heart Failure Treatment Outlook

Sep 02 2019

Keeping Track: FDA Starts November With A Bang

Nov 02 2018

AstraZeneca: DECLARE-TIMI Outcomes May Support Competitive Claim For Farxiga In Heart Failure

Nov 13 2018

BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim

Dec 02 2016

AZ's Forxiga Gets Type 1 Diabetes EU Okay As Sanofi Suffers US Setback

Mar 25 2019

Related Companies

AstraZeneca PLC

Johnson & Johnson

Eli Lilly and Company

Boehringer Ingelheim GmbH

Additional Topics

United States Approvals Regulation Cardiovascular Metabolic Disorders BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.